Form 4: Quest Diagnostics SVP Sells Shares in Routine Transactions
Insider Transaction Report
Quest Diagnostics SVP Patrick Plewman reported sales of company common stock totaling 640 shares through tax-related and pre-planned transactions.
Summary
- Patrick Plewman, Senior Vice President for Diagnostic Services at Quest Diagnostics Inc. (DGX), reported two transactions involving the sale of common stock.
- On March 2, 2026, Plewman disposed of 230 shares of common stock at a price of $204.86 per share.
- This sale was conducted to satisfy tax obligations arising from the vesting of previously granted restricted share units.
- On March 3, 2026, an additional 410 shares of common stock were sold at a price of $207.73 per share.
- This second sale was executed pursuant to a Rule 10b5-1 sales plan, which was adopted by the reporting person.
- Following these transactions, Patrick Plewman beneficially owns 15,198 shares of Quest Diagnostics common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event. The sales are attributed to routine tax obligations from RSU vesting and a pre-arranged 10b5-1 plan, which are common and do not typically reflect a change in the insider's confidence in the company.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future performance.
Industry Context
StockSavvy.ai notes that insider sales, particularly those explicitly stated as being for tax obligations or executed under a pre-arranged Rule 10b5-1 plan, are common occurrences. These types of transactions are generally considered routine and do not typically signal a change in management's fundamental outlook on the company's prospects or financial health.
Stakeholder Impact
- Shareholders: The sale of shares by an executive slightly reduces their direct ownership stake, but given the reasons (tax and 10b5-1 plan), it is unlikely to be perceived as a negative signal for the company's future performance.
Key Dates
| Date | Description |
|---|---|
| 03/02/2026 | Sale of 230 shares of common stock to satisfy tax obligations. |
| 03/03/2026 | Sale of 410 shares of common stock pursuant to a Rule 10b5-1 sales plan. |
| 03/04/2026 | Date the Form 4 was signed by the attorney in fact for Patrick Plewman. |
Keywords
Quest Diagnostics, DGX, Insider Transaction, Form 4, Stock Sale, Executive Compensation, Rule 10b5-1 Plan, Tax Obligation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.